UBS cuts target for ACADIA Pharmaceuticals stock to USD 23.00

Published on 10/15/2026 at 19:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 308.00 million. ACADIA Pharmaceuticals stock costs EUR 17.55 on October 15, 2026 at 7:41 p.m. CEST.

Analyst view and valuation

UBS cut its ACADIA Pharmaceuticals target from USD 49.00 to USD 23.00 on October 13, 2026.
ACADIA Pharmaceuticals reported USD 308.00 million in revenue for the second quarter of 2026.
ACADIA Pharmaceuticals stock costs EUR 17.55 at Lang & Schwarz on October 15, 2026 at 7:41 p.m. CEST.
ACADIA Pharmaceuticals had a P/E ratio of 8.86 and a market capitalization of USD 3.4 billion on October 15, 2026.

ACAD, US0042251084, Illustration mit AI erstellt.

ACADIA Pharmaceuticals (US0042251084) was given a USD 23.00 price target by UBS on October 13, 2026, down from USD 49.00, while the firm moved its rating from Buy to Neutral, according to MarketBeat. Using the Nasdaq price of USD 19.67 on October 15, 2026 at 1:46 p.m. ET, the new target stood 16.93 percent above the share price. At Lang & Schwarz, the stock was trading at EUR 17.55 on October 15, 2026 at 7:41 p.m. CEST, in after-hours trading.

Quarterly revenue and earnings

Acadia reported USD 308.00 million in revenue for the second quarter of 2026, compared with USD 296.55 million expected by analysts. Adjusted earnings per share came to USD 0.18, above the USD 0.07 consensus estimate, according to MarketBeat. The company develops and commercializes medicines for central nervous system disorders and rare diseases.

Price position in US trading

The Nasdaq price was USD 19.67 on October 15, 2026 at 1:46 p.m. ET. The 52-week range was USD 18.39 to USD 30.96, putting the quote USD 1.28 above the low and USD 11.29 below the high. Trading volume stood at 600,502 shares against an average volume of 1,860,675 shares.

Valuation and peer context

ACADIA Pharmaceuticals had a market capitalization of USD 3.4 billion and a P/E ratio of 8.86 on October 15, 2026. Its dividend yield was 0.00 percent. The latest reported results were released on August 4, 2026, covering the second quarter.

Comparison with peers

ACAD (Nasdaq, USD): P/E 8.86, market capitalization USD 3.4 billion.

Neurocrine Biosciences (Nasdaq, USD): plus 0.84 percent, P/E 20.10, market capitalization USD 13.9 billion.

Axsome Therapeutics (Nasdaq, USD): plus 1.33 percent, P/E minus 43.87, market capitalization USD 8.6 billion.

After-hours euro quote

The euro quotation gives German investors a separate evening reference for the US-listed biotech. Its Nasdaq valuation remains the relevant home-market frame, while the UBS target reset and the latest quarterly figures provide the main dated reference points.

The further course of trading is shown by the continuously updated real-time quote of ACADIA Pharmaceuticals stock.